To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO in Multiple Myeloma
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multicenter trialparallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO + dexamethasone in the participants with relapsed or refractory Multiple Myeloma.